NASDAQ$VRCA

Verrica Pharmaceuticals Inc · Q1 2017 earnings

Q1 2017 earnings · · Investor relations

Headline financials

EPS (adj)

-$0.03

No prior period
Net Income

-$570K

No prior period
Operating Income

-$570K

No prior period
Gross Profit

$0.00

No prior period
R&D Expense

$515K

No prior period

Revenue & EPS history

Verrica · Revenue · Quarterly

$5.02M

Q1 2026+46.1%vs Q1 2025
Beat estimate in 9 of 14 quarters(64%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports

Historical avg

-2.7%

Avg return

Earnings day

-3.4%

Avg return

5 days after

-0.4%

Avg return

30 days after

42%

13 / 31 earnings

Positive

+18.6%

Q1 2024

Best reaction

-47.9%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.8%-15.3%
Q4 2025+4.7%+3.2%-14.5%
Q3 2025+3.2%+15.8%+104.7%
Q1 2025+2.9%-0.8%-3.0%
Q4 2024-7.6%+0.5%-25.3%
Q3 2024-47.9%-45.8%-22.2%
Q2 2024-44.8%-43.8%-62.6%
Q1 2024+18.6%+8.4%+7.3%
Q4 2023-3.0%-10.1%+3.5%
Q3 2023-13.6%-17.7%+7.6%
Q2 2023+7.6%+1.6%-18.5%
Q1 2023-1.4%-7.1%-13.9%
Q4 2022-6.9%+1.5%-21.6%
Q3 2022-3.1%+3.1%+43.7%
Q2 2022+17.1%+9.6%+18.8%
Q1 2022-1.6%-7.8%-63.0%
Q4 2021+1.3%-7.7%+1.9%
Q3 2021-4.2%-5.9%-22.2%
Q2 2021-1.6%-0.7%+12.6%
Q1 2021-0.8%-0.2%-14.8%
Q4 2020-9.6%-0.2%+1.3%
Q3 2020+13.9%+13.1%+32.3%
Q2 2020+5.6%+4.8%+29.6%
Q1 2020+10.5%+2.8%+24.0%
Q4 2019-12.1%-7.5%+31.3%
Q3 2019+0.8%+4.0%-7.3%
Q2 2019+2.6%-9.3%-2.3%
Q1 2019+1.0%-3.3%-23.4%
Q4 2018-7.5%+1.1%-8.0%
Q3 2018-3.8%+5.6%-22.7%
Q2 2018-0.9%+2.7%+13.8%
Q1 2018
Q4 2017
Q3 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro